Press release
Global Blood Cancer Drugs Market worth $55.6 billion by 2025: Major Key Players Johnson & Johnson Inc., Amgen Inc., Bayer AG., Pfizer Inc., Eli Lily & Co., AstraZeneca, AbbVie Inc. and other.
Polaris Market Research presents a most up-to-date research on " Global Blood Cancer Drugs Market [By Blood Cancer Type (Leukemia (Acute Myeloid Leukemia, Chronic Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Lymphocytic Leukemia), Lymphoma (Hodgkin Lymphoma, Non-Hodgkin Lymphoma (B-Cell Lymphoma, T-Cell Lymphoma)), and Myeloma; By Drugs (Rituaxan/Mabthera (Rituximab), Gleevac/Glivec (Imatinib), Revlimid (Lenalidomide), Velcade (Bortezomib), Tasigna (Nilotinib), Pomalyst (Pomalidomide), Vidaza (Azacitidine), Kyprolis (Carfilzomib), Adcetris (Brentuximab Vedotin), and Others); By Treatment Approaches (Chemotherapeutic, mAbs/Targeted Therapies, and Immunotherapeutic); By Region]: Market Size & Forecast, 2017 – 2025". The global blood cancer drugs market is anticipated to reach USD 55.6 billion by 2025 according to a new report published by Polaris Market Research.The demand for blood cancer drug is primarily driven by growing death incidences by blood cancer, and continuous innovation for developing novel treatments with the help of several ongoing clinical trials. Moreover, increasing research and development of biological and targeted therapies as treatment will spur the blood cancer drugs market during the upcoming period. However, the high price of drugs and the stringent government policies will limit the growth of blood cancer drugs market during the forecast period.
Request for sample report of blood cancer drugs market analysis: https://www.polarismarketresearch.com/industry-analysis/global-blood-cancer-drugs-market/request-for-free-sample
Most of the blood cancers start in the bone marrow, where blood is produced. In blood cancer the growth of normal blood cells is dislodged by the uncontrollable growth of abnormal blood cells. These cancerous cells prevent the blood from performing many of its functions. Hence, the existing treatments of blood cancer are being the foundation for developing the new drugs. The steady flow of the blood cancer drugs has created opportunity for research and development in the existing market. For instance, Amgen Inc. received approval for BLINCYTO in July 2017, which is used in treating B-cell precursor Acute Lymphoblastic leukemia. Similarly, European blood cancer drugs market witnessed the approvals of Gazyvaro, by Roche AG that is used in treating advanced follicular lymphoma. Also, novel technologies like CAR-T are likely to be launched this year.
The global blood cancer drugs market is segmented into blood cancer type, drugs and treatment approaches. On the basis of blood cancer type, the global blood cancer drugs market is segmented into leukemia, lymphoma and myeloma. The lymphoma segment is expected to drive the majority market of blood cancer drugs followed by leukemia. The global market of this segment is primarily driven by the increasing prevalence of lymphoma, and presence of effective treatments in the market. On the basis of drugs, the global blood cancer drugs market is further categorized into Rituaxan/Mabthera (Rituximab), Gleevac/Glivec (Imatinib), Revlimid (Lenalidomide), Velcade (Bortezomib), Tasigna (Nilotinib), Pomalyst (Pomalidomide), Vidaza (Azacitidine), Kyprolis (Carfilzomib), Adcetris (Brentuximab Vedotin), and Others. This continuous innovation for treating various sub-types of blood cancers has led to the development of novel types of treatments. For instance, the combination of Revlimid and Velcade has emerged as the preferential drugs in trials for treating multiple myeloma.
On the basis of treatment approaches the global blood cancer drugs market is further segmented into Chemotherapeutic, mAbs/Targeted Therapies, and Immunotherapeutic. Due to availability of variety of chemotherapeutic agent in the market chemotherapeutic drugs are expected to hold the higher share in blood cancer drugs market. Moreover, their effectiveness for the treatment of blood cancer and increasing number of cancer patients globally has garnered more demand for chemotherapeutic drugs throughout the world.
Browse report summary of blood cancer drugs market report: https://www.polarismarketresearch.com/industry-analysis/global-blood-cancer-drugs-market
Geographically, the global blood cancer drugs market is segmented into North America, Europe, Asia Pacific, and the rest of the world. North America dominates the blood cancer drugs market which is followed by Europe and Asia Pacific. Favorable reimbursement policies, surge in R&D investments of various companies, as well as the increase in the number of blood cancer treatments are some of the major factors responsible for the growth of North America’s blood cancer drugs market. Moreover, Asia-Pacific region has been identified as the lucrative market for the for-blood cancer drugs due to increasing awareness of the use of these drugs, increased healthcare expenditure, and rising per capita disposable income. These are some of the major factors which are influencing the growth of the blood cancer drugs in Asia-pacific region.
Major Key Players:
• Johnson & Johnson Inc.
• Amgen Inc.
• Bayer AG.
• Pfizer, Inc.
• AbbVie Inc.
• Roche Holding AG.
• Celgene Corporation
• AstraZeneca
• Novartis AG
• GlaxoSmithKline PLC
• Merck & Co., Inc.
• Eli Lily & Co.
Key Findings from the study suggest blood cancer drugs in the market are much innovative and manufacturers are progressively concentrating on innovation of combination drugs. Companies are in a stage of development of new drugs in order to provide novel treatments for blood cancer. The immunotherapy segment is anticipated to grow at a high growth rate over the forecast period. The growth of this segment is primarily driven by increased awareness for its use as an alternative and effective treatment for blood cancer. North America is presumed to dominate the global blood cancer drugs market over the forecast period. Asia Pacific region which shows signs of high growth potential owing to the booming economies of India, and China.
Make an inquiry of blood cancer drugs market report: https://www.polarismarketresearch.com/industry-analysis/global-blood-cancer-drugs-market/inquire-before-buying
Key Segments:
Blood cancer drugs by Blood Cancer Type
• Lymphoma
• T-cell Lymphoma
• Leukemia
• Myeloma
Blood cancer drugs by Drugs
• Rituaxan/Mabthera (Rituximab)
• Gleevac/Glivec (Imatinib)
• Revlimid (Lenalidomide)
• Velcade (Bortezomib)
• Tasigna (Nilotinib)
• Pomalyst (Pomalidomide)
• Vidaza (Azacitidine)
• Kyprolis (Carfilzomib)
• Adcetris (Brentuximab Vedotin)
• Others
Blood cancer drugs by Treatment Approaches
• Chemotherapeutic
• mAbs/Targeted Therapies
• Immunotherapeutic
About Polaris Market Research
Polaris Market Research is a global market research and consulting company. The company specializes in providing exceptional market intelligence and in-depth business research services for our clientele spread across different enterprises. We at Polaris are obliged to serve our diverse customer base present across the industries of healthcare, technology, semi-conductors and chemicals among various other industries present around the world. We strive to provide our customers with updated information on innovative technologies, high growth markets, emerging business environments and latest business-centric applications, thereby helping them always to make informed decisions and leverage new opportunities. Adept with a highly competent, experienced and extremely qualified team of experts comprising SMEs, analysts and consultants, we at Polaris endeavor to deliver value-added business solutions to our customers.
Contact us
Mr. Rohit
Corporate Sales, USA
Polaris Market Research
Phone: 1-646-568-9980
Email: sales@polarismarketresearch.com
Web: www.polarismarketresearch.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Global Blood Cancer Drugs Market worth $55.6 billion by 2025: Major Key Players Johnson & Johnson Inc., Amgen Inc., Bayer AG., Pfizer Inc., Eli Lily & Co., AstraZeneca, AbbVie Inc. and other. here
News-ID: 1592149 • Views: …
More Releases from Polaris Market Research & Consulting

Granite Market Projected to Reach USD 6.63 Billion by 2034, Growing at a CAGR of …
Polaris Market Research has released new insights into the Granite market, highlighting key developments, evolving trends, and growth prospects across major regions and segments. The report delivers an in-depth analysis of market dynamics, competitive shifts, and strategic outlooks to support informed decision-making for businesses and investors.
Market at a Glance
In 2024, the market was valued at USD 3.99 billion and is anticipated to grow to USD 6.63 Billion by 2034. It…

Molecular Diagnostics for Sexually Transmitted Diseases Market to Reach USD 7.85 …
Polaris Market Research announces the release of its latest study on the Molecular Diagnostics For Sexually Transmitted Diseases market. It offers comprehensive insights into all the key market aspects, including industry trends, market dynamics, competitive landscape, and strategic developments. The report is designed to help stakeholders make strategic decisions in the rapidly evolving market landscape.
According to the findings, the market stood at 3.82 billion in 2024 and is expected to…

Higher Alpha Olefins Market Projected to Hit USD 20.01 Billion by 2034, Expandin …
Polaris Market Research announces the release of its latest study on the Higher Alpha Olefins market. It offers comprehensive insights into all the key market aspects, including industry trends, market dynamics, competitive landscape, and strategic developments. The report is designed to help stakeholders make strategic decisions in the rapidly evolving market landscape.
According to the findings, the market stood at 10.39 billion in 2024 and is expected to reach 20.01 billion…

Direct Oral Anticoagulants (DOACs) Device Market to Reach USD 64.83 Billion by 2 …
Polaris Market Research announces the release of its latest study on the Direct Oral Anticoagulants (DOACs) Device market. It offers comprehensive insights into all the key market aspects, including industry trends, market dynamics, competitive landscape, and strategic developments. The report is designed to help stakeholders make strategic decisions in the rapidly evolving market landscape.
According to the findings, the market stood at 31.67 billion in 2024 and is expected to reach…
More Releases for Blood
Global Blood Processing Consumables(CH 5) Market Size - By Product Type(blood ad …
Market Overview and Report Coverage
Blood Processing Consumables encompass various products and materials used in the collection, storage, processing, and transfusion of blood and blood components. This category includes items like blood bags, tubes, filters, and reagents essential for laboratories and hospitals in ensuring safe and effective blood management.
The current outlook for the Blood Processing Consumables market indicates robust growth driven by increasing healthcare needs, advancements in medical technology, and a…
Medical Blood Bag Market 2027 Global Analysis and Forecasts by Type (Single Bloo …
The medical blood bags are the instruments that are used to store, collect, transport, and transfuse blood and its components. The disposable blood bags replaced the use of glass bottles due to problems associated with the use of glass bottles including insufficient sterility, leading to contamination of the blood, and the development of air bubbles resulted in severe complications during blood transfusion.
Access Sample Report@: https://bit.ly/3rGMS4Q
Leading Players in the…
Global Blood coagulation analyzer Market, Blood coagulation analyzer Market 2020 …
The Blood coagulation analyzer market report provides a comprehensive view of global Blood coagulation analyzer industry. The study provides the industry overview with its growth analysis including CAGR, market shares, sales, gross margin, value, future trends, market opportunities etc. The study also includes analysis of historic data from 2015 to 2019 along with forecast from 2020 to 2025. Further, the Blood coagulation analyzer report contains drivers andrestraints of Blood coagulation…
Blood Bank (Blood Banking) Market 2019 Analysis By American Red Cross, Japan Red …
According to this study, over the next five years the Blood Bank (Blood Banking) market will register a 7.7% CAGR in terms of revenue, the global market size will reach US$ 40500 million by 2024, from US$ 26000 million in 2019.
Blood Bank (Blood Banking) Market reports also offer important insights which help the industry experts, product managers, CEOs, and business executives to draft their policies on various parameters including expansion,…
Blood Bank (Blood Banking) Market Stay on The top of this growing business Indus …
Reports Monitor released a new Global Blood Bank (Blood Banking) Market research study with over 100 industry informative desk and Figures spread through Pages and an in-depth TOC on “Blood Bank (Blood Banking) Market”.
Global Blood Bank (Blood Banking) market 2019 research lays out the knowledge to achieve positive growth and presents different methods for maximizing your profit. The market study puts forward estimates for Global Blood Bank (Blood Banking) Market 2019 analysis and Forecast…
Blood Bank And Plasma Freezers Market Report 2018: Segmentation by Type (Common …
Global Blood Bank And Plasma Freezers market research report provides company profile for Follett, Glen Dimplex, Kirsch, LABCOLD, Lorne Laboratories, REMI GROUP, Telstar Group, LabRepCo, Helmer Scientific, Haier Bio-Medical, Panasonic Healthcare, Thermo Fisher, Dometic and Others.
This market study includes data about consumer perspective, comprehensive analysis, statistics, market share, company performances (Stocks), historical analysis 2012 to 2017, market forecast 2018 to 2025 in terms of volume, revenue, YOY growth rate,…